Tag: Pfizer

Clinical Trials News Oncology

Pfizer and Astellas Announce Landmark Survival Benefit with XTANDI in Prostate Cancer Trial

pfizer news

Pfizer and Astellas report groundbreaking Phase 3 EMBARK trial results showing XTANDI® (enzalutamide) plus leuprolide significantly improves overall survival in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC) and high-risk biochemical recurrence. This marks the first time an androgen receptor inhibitor-based therapy has shown a definitive survival benefit in this specific patient population, offering new hope for extending lives through early and effective treatment.

Clinical Trials Cancer Healthcare & Pharmaceuticals News

Pfizer’s BRAFTOVI® Combination Regimen Halves Mortality Risk in BRAF V600E-Mutant Metastatic Colorectal Cancer

pfizer news

Pfizer’s BRAFTOVI® combination regimen has demonstrated a 51% reduction in the risk of death and a 47% decrease in disease progression for patients with BRAF V600E-mutant metastatic colorectal cancer, according to the pivotal Phase 3 BREAKWATER trial.

Healthcare & Pharmaceuticals Cancer Clinical Trials News

Astellas and Pfizer’s XTANDI® Demonstrates Significant Long-Term Survival Benefit in Metastatic Hormone-Sensitive Prostate Cancer

pfizer news

XTANDI® (enzalutamide), co-developed by Astellas and Pfizer, has shown a significant 30% reduction in risk of death over five years in metastatic hormone-sensitive prostate cancer (mHSPC) patients, marking it as the first androgen receptor inhibitor to demonstrate this long-term survival benefit.